https://www.medikine.com/job-postings daily 0.75 2022-06-02 https://www.medikine.com/job-postings/category/Protein+Sciences monthly 0.5 https://www.medikine.com/job-postings/category/Peptide+Discovery monthly 0.5 https://www.medikine.com/job-postings/category/Immunology monthly 0.5 https://www.medikine.com/publicationsandpresentations daily 0.75 2022-11-10 https://www.medikine.com/publicationsandpresentations/9sd671g2ogabmzp40nox6ww8pqzp5p monthly 0.5 2022-03-04 https://www.medikine.com/publicationsandpresentations/tpv6mm2jn5045e8p5sr1iev551ejwb monthly 0.5 2022-02-28 https://www.medikine.com/publicationsandpresentations/v3r91onl4hw2r0xh53bmd7uz8paw6d monthly 0.5 2022-02-28 https://www.medikine.com/publicationsandpresentations/wq3zpfhdsdkp4me3q10ydgqa42jr4d monthly 0.5 2022-02-28 https://www.medikine.com/publicationsandpresentations/j76669nh46w01dzbta5kjadht7suxe monthly 0.5 2022-02-28 https://www.medikine.com/publicationsandpresentations/9sd671g2ogabmzp40nox6ww8pqzp5p-x86w3 monthly 0.5 2022-04-11 https://www.medikine.com/publicationsandpresentations/9sd671g2ogabmzp40nox6ww8pqzp5p-rfgap monthly 0.5 2022-05-10 https://www.medikine.com/publicationsandpresentations/9sd671g2ogabmzp40nox6ww8pqzp5p-rfgap-mr59c-tpgny monthly 0.5 2022-11-10 https://www.medikine.com/publicationsandpresentations/9sd671g2ogabmzp40nox6ww8pqzp5p-rfgap-mr59c monthly 0.5 2022-11-10 https://www.medikine.com/press-releases daily 0.75 2023-06-12 https://www.medikine.com/press-releases/medikine-to-highlight-preclinical-data-on-its-lead-program-mdk-703-an-il-7-mimetic-at-the-2022-annual-meeting-of-the-american-association-for-cancer-research-aacr monthly 0.5 2022-04-06 https://www.medikine.com/press-releases/medikine-initiates-first-clinical-trial-of-its-lead-program-an-interleukin-7-mimetic monthly 0.5 2022-10-05 https://www.medikine.com/press-releases/medikine-initiates-first-clinical-trial-of-its-lead-program-an-interleukin-7-mimetic-952pw monthly 0.5 2022-10-05 https://www.medikine.com/press-releases/medikine-initiates-first-clinical-trial-of-its-lead-program-an-interleukin-7-mimetic-952pw-xzaxl monthly 0.5 2022-12-06 https://www.medikine.com/press-releases/medikine-appoints-roland-buelow-phd-to-board-of-directors monthly 0.5 2022-12-06 https://www.medikine.com/pipeline daily 0.75 2022-08-04 https://www.medikine.com/privacy-policy daily 0.75 2022-03-03 https://www.medikine.com/contact daily 0.75 2023-12-04 https://images.squarespace-cdn.com/content/v1/620c07e40af1b05bc82bc766/7ce73f0c-ae2e-4d4d-8bf4-476902db9b58/Map.png Contact - Get in touch Medikine, Inc. 4275 Executive Square, Suite 200, #1079 San Diego, CA 92037 Phone (650) 529-7472 Email For general inquiries: info@medikine.com For business development inquiries: BD@medikine.com For career inquiries: HR@medikine.com https://www.medikine.com/home daily 1.0 2024-02-27 https://images.squarespace-cdn.com/content/v1/620c07e40af1b05bc82bc766/57ca1ba7-6331-4182-a34f-33ec06dc20b3/SEB+JANIAK_MIMESIS_Lacus+Luxuriae+2017.jpg Home - A New Generation of Medicines Engineering cytokine mimetics to change the course of serious diseases https://images.squarespace-cdn.com/content/v1/620c07e40af1b05bc82bc766/8f3507cd-a077-4cb6-9f63-ea51e821c58d/SEB+JANIAK_MIMESIS_Lacus+Luxuriae+2017.jpg Home - Make it stand out Whatever it is, the way you tell your story online can make all the difference. https://images.squarespace-cdn.com/content/v1/620c07e40af1b05bc82bc766/03e5e6ab-d25a-47b4-b9a3-90b3134362c2/AdobeStock_153231640.jpg Home - Unique Advantages of PEPTIKINES PEPTIKINESᵀᴹ are substantially smaller molecules than cytokines, making them readily amenable to enhancement for desired pharmacokinetics or added pharmacologic features, including cell targeting and conditional activation. Because PEPTIKINES are structurally unrelated to natural cytokines, they do not generate neutralizing antibodies to cytokines. https://www.medikine.com/about daily 0.75 2022-06-01 https://images.squarespace-cdn.com/content/v1/620c07e40af1b05bc82bc766/4fc49837-1235-4555-9809-b8bd7d570043/iStock-1162215224.jpg About - How We Get There We have already had success in identifying PEPTIKINES for multiple receptor targets and will continue to explore the platform’s utility across the hundreds of cytokine receptor targets relevant to human disease. Through the lens of our expertise, we’re identifying the right investigational medicines that will push the boundaries of what success looks like for people living with cancer, autoimmune disorders, and infectious diseases. https://www.medikine.com/science daily 0.75 2022-06-01 https://images.squarespace-cdn.com/content/v1/620c07e40af1b05bc82bc766/1646434682788-FQC18HBJPPEZBIQH6ILH/Platform_1-100.jpg Science https://images.squarespace-cdn.com/content/v1/620c07e40af1b05bc82bc766/1647454737121-3CILIOGZNJS78E2659MK/Platform_2.jpg Science https://images.squarespace-cdn.com/content/v1/620c07e40af1b05bc82bc766/2d64ce7a-7cf3-4f84-a16d-a0831182e70f/myimage_lht.png Science - PEPTIKINES have unique advantages over cytokine modification approaches PEPTIKINES are designed with no reference to cytokine or receptor structure. They are engineered for low immunogenicity, and since they are unrelated in sequence to the natural cytokine, there’s little risk of generating antibodies that neutralize the endogenous cytokine. This was a major differentiating feature of unprecedented discoveries made in the 1990s by Medikine’s founders. Their discovery of novel peptide agonists of the EPO and TPO receptors led to the development of Omontys® and Nplate®, respectively. https://www.medikine.com/careers daily 0.75 2022-03-04 https://images.squarespace-cdn.com/content/v1/620c07e40af1b05bc82bc766/60321f72-c050-4941-abcf-469ad8b4b3b1/iStock-506859726.jpg Careers - Are you the unique individual who can help us create the extraordinary? Let’s build what’s next. https://www.medikine.com/news daily 0.75 2022-05-10 https://www.medikine.com/team-2 daily 0.75 2022-05-17 https://images.squarespace-cdn.com/content/v1/620c07e40af1b05bc82bc766/1645079657897-WC4E3X6BIFZLYVX7R7OE/SamsaraBioCapital-horizontal-fullcolor+1.png Team (Original) https://images.squarespace-cdn.com/content/v1/620c07e40af1b05bc82bc766/1645079658372-ZJ2U99GBDV8HJMUV7Q7I/Lightspeed-2+1.png Team (Original) https://images.squarespace-cdn.com/content/v1/620c07e40af1b05bc82bc766/1645079657907-50YVQQ1GTLL7GEI8CO02/Bluebird+1.png Team (Original) https://images.squarespace-cdn.com/content/v1/620c07e40af1b05bc82bc766/1645127591022-0AXK1AD9I9DE1PWOA1LV/Ron+-+jacket+1.jpg Team (Original) https://images.squarespace-cdn.com/content/v1/620c07e40af1b05bc82bc766/1645127655097-MMC1YNL00WNMZCVREP1U/Gia+1.jpg Team (Original) https://images.squarespace-cdn.com/content/v1/620c07e40af1b05bc82bc766/1645127711874-KK3OVTN41G9R2YLV6BEO/BD1+1.jpg Team (Original) https://images.squarespace-cdn.com/content/v1/620c07e40af1b05bc82bc766/1645127743845-PMAHCTOMGIK9CG2GT8RN/Joseph+Leveque+Formal+No+Tie+2.jpg Team (Original) https://images.squarespace-cdn.com/content/v1/620c07e40af1b05bc82bc766/1645127781291-7SID082LW9FP2WGVC6KB/Needels+020922+1.jpg Team (Original) https://www.medikine.com/marcos-milla-phd daily 0.75 2023-06-15 https://images.squarespace-cdn.com/content/v1/620c07e40af1b05bc82bc766/be9a7e13-d216-4368-9f82-1e49c1c8a193/SYNTHORX_Marcos%2BMilla%2B001.jpg Marcos Milla, PhD - Make it stand out Whatever it is, the way you tell your story online can make all the difference. https://www.medikine.com/william-j-dower-phd daily 0.75 2022-05-17 https://images.squarespace-cdn.com/content/v1/620c07e40af1b05bc82bc766/1645127711874-KK3OVTN41G9R2YLV6BEO/BD1+1.jpg William J. Dower, PhD - Ronald W. Barrett, PhD CEO AND CHAIRMAN OF THE BOARD Ronald W. Barrett, PhD, is the CEO and Chairman of the Board of Directors of Medikine. Ron is the former CEO and a Director of XenoPort, Inc. (XNPT), a public biopharmaceutical company he co-founded in 1999, which was acquired by Arbor Pharmaceuticals in 2016. Under his guidance, XenoPort completed multiple private and public financings and business development partnerships and advanced five in-house compounds into clinical trials. Ron led the company’s efforts that resulted in the FDA approval of HORIZANT® (gabapentin enacarbil), the first and only non-dopaminergic drug for moderate-to-severe restless legs syndrome (RLS) in the US. Prior to XenoPort, Ron was Senior Vice President of Research at Affymax Research Institute, where he pioneered the development and use of new drug discovery technology – work that led to two FDA-approved medicines. Ron began his career in the neuroscience drug discovery group at Abbott Laboratories. He currently serves on the Board of Directors of Concert Pharmaceuticals, Inc. (Nasdaq:CNCE); Janux Therapeutics, Inc. (Nasdaq:JANX); and Quadriga Biosciences, Inc. Ron has co-authored over 50 manuscripts from peer-reviewed journals and is an inventor of over 50 issued patents in the US. He received a BS in Biology from Bucknell University and a PhD in Pharmacology from Rutgers University. https://www.medikine.com/gianna-m-bosko daily 0.75 2022-02-21 https://images.squarespace-cdn.com/content/v1/620c07e40af1b05bc82bc766/1645127655097-MMC1YNL00WNMZCVREP1U/Gia+1.jpg Gianna M. Bosko - Ronald W. Barrett, PhD CEO AND CHAIRMAN OF THE BOARD Ronald W. Barrett, PhD, is the CEO and Chairman of the Board of Directors of Medikine. Ron is the former CEO and a Director of XenoPort, Inc. (XNPT), a public biopharmaceutical company he co-founded in 1999, which was acquired by Arbor Pharmaceuticals in 2016. Under his guidance, XenoPort completed multiple private and public financings and business development partnerships and advanced five in-house compounds into clinical trials. Ron led the company’s efforts that resulted in the FDA approval of HORIZANT® (gabapentin enacarbil), the first and only non-dopaminergic drug for moderate-to-severe restless legs syndrome (RLS) in the US. Prior to XenoPort, Ron was Senior Vice President of Research at Affymax Research Institute, where he pioneered the development and use of new drug discovery technology – work that led to two FDA-approved medicines. Ron began his career in the neuroscience drug discovery group at Abbott Laboratories. He currently serves on the Board of Directors of Concert Pharmaceuticals, Inc. (Nasdaq:CNCE); Janux Therapeutics, Inc. (Nasdaq:JANX); and Quadriga Biosciences, Inc. Ron has co-authored over 50 manuscripts from peer-reviewed journals and is an inventor of over 50 issued patents in the US. He received a BS in Biology from Bucknell University and a PhD in Pharmacology from Rutgers University. https://www.medikine.com/michael-c-needels-phd daily 0.75 2023-10-03 https://images.squarespace-cdn.com/content/v1/620c07e40af1b05bc82bc766/1645127781291-7SID082LW9FP2WGVC6KB/Needels+020922+1.jpg Michael C. Needels, PhD - Ronald W. Barrett, PhD CEO AND CHAIRMAN OF THE BOARD Ronald W. Barrett, PhD, is the CEO and Chairman of the Board of Directors of Medikine. Ron is the former CEO and a Director of XenoPort, Inc. (XNPT), a public biopharmaceutical company he co-founded in 1999, which was acquired by Arbor Pharmaceuticals in 2016. Under his guidance, XenoPort completed multiple private and public financings and business development partnerships and advanced five in-house compounds into clinical trials. Ron led the company’s efforts that resulted in the FDA approval of HORIZANT® (gabapentin enacarbil), the first and only non-dopaminergic drug for moderate-to-severe restless legs syndrome (RLS) in the US. Prior to XenoPort, Ron was Senior Vice President of Research at Affymax Research Institute, where he pioneered the development and use of new drug discovery technology – work that led to two FDA-approved medicines. Ron began his career in the neuroscience drug discovery group at Abbott Laboratories. He currently serves on the Board of Directors of Concert Pharmaceuticals, Inc. (Nasdaq:CNCE); Janux Therapeutics, Inc. (Nasdaq:JANX); and Quadriga Biosciences, Inc. Ron has co-authored over 50 manuscripts from peer-reviewed journals and is an inventor of over 50 issued patents in the US. He received a BS in Biology from Bucknell University and a PhD in Pharmacology from Rutgers University. https://www.medikine.com/christopher-heery-md daily 0.75 2022-02-21 https://www.medikine.com/shelley-chu-md-phd daily 0.75 2022-02-21 https://www.medikine.com/joseph-leveque-md daily 0.75 2023-01-15 https://images.squarespace-cdn.com/content/v1/620c07e40af1b05bc82bc766/1645127743845-PMAHCTOMGIK9CG2GT8RN/Joseph+Leveque+Formal+No+Tie+2.jpg Joseph Leveque, MD - Ronald W. Barrett, PhD CEO AND CHAIRMAN OF THE BOARD Ronald W. Barrett, PhD, is the CEO and Chairman of the Board of Directors of Medikine. Ron is the former CEO and a Director of XenoPort, Inc. (XNPT), a public biopharmaceutical company he co-founded in 1999, which was acquired by Arbor Pharmaceuticals in 2016. Under his guidance, XenoPort completed multiple private and public financings and business development partnerships and advanced five in-house compounds into clinical trials. Ron led the company’s efforts that resulted in the FDA approval of HORIZANT® (gabapentin enacarbil), the first and only non-dopaminergic drug for moderate-to-severe restless legs syndrome (RLS) in the US. Prior to XenoPort, Ron was Senior Vice President of Research at Affymax Research Institute, where he pioneered the development and use of new drug discovery technology – work that led to two FDA-approved medicines. Ron began his career in the neuroscience drug discovery group at Abbott Laboratories. He currently serves on the Board of Directors of Concert Pharmaceuticals, Inc. (Nasdaq:CNCE); Janux Therapeutics, Inc. (Nasdaq:JANX); and Quadriga Biosciences, Inc. Ron has co-authored over 50 manuscripts from peer-reviewed journals and is an inventor of over 50 issued patents in the US. He received a BS in Biology from Bucknell University and a PhD in Pharmacology from Rutgers University. https://www.medikine.com/ronald-w-barrett-phd daily 0.75 2023-06-30 https://www.medikine.com/terms-of-use daily 0.75 2022-03-04 https://www.medikine.com/team daily 0.75 2023-10-03 https://images.squarespace-cdn.com/content/v1/620c07e40af1b05bc82bc766/1645079657897-WC4E3X6BIFZLYVX7R7OE/SamsaraBioCapital-horizontal-fullcolor+1.png Team https://images.squarespace-cdn.com/content/v1/620c07e40af1b05bc82bc766/1645079658372-ZJ2U99GBDV8HJMUV7Q7I/Lightspeed-2+1.png Team https://images.squarespace-cdn.com/content/v1/620c07e40af1b05bc82bc766/1645079657907-50YVQQ1GTLL7GEI8CO02/Bluebird+1.png Team https://images.squarespace-cdn.com/content/v1/620c07e40af1b05bc82bc766/1645127743845-PMAHCTOMGIK9CG2GT8RN/Joseph+Leveque+Formal+No+Tie+2.jpg Team https://images.squarespace-cdn.com/content/v1/620c07e40af1b05bc82bc766/1654126257617-ZUJWA3VO1AYEHEJZ1TEL/SYNTHORX_Marcos%2BMilla%2B001.jpg Team https://www.medikine.com/roland-buelow-phd daily 0.75 2022-12-06 https://www.medikine.com/team-1 daily 0.75 2023-10-03 https://images.squarespace-cdn.com/content/v1/620c07e40af1b05bc82bc766/1645079657897-WC4E3X6BIFZLYVX7R7OE/SamsaraBioCapital-horizontal-fullcolor+1.png Team (Copy) https://images.squarespace-cdn.com/content/v1/620c07e40af1b05bc82bc766/1645079658372-ZJ2U99GBDV8HJMUV7Q7I/Lightspeed-2+1.png Team (Copy) https://images.squarespace-cdn.com/content/v1/620c07e40af1b05bc82bc766/1645079657907-50YVQQ1GTLL7GEI8CO02/Bluebird+1.png Team (Copy) https://images.squarespace-cdn.com/content/v1/620c07e40af1b05bc82bc766/1645127743845-PMAHCTOMGIK9CG2GT8RN/Joseph+Leveque+Formal+No+Tie+2.jpg Team (Copy) https://images.squarespace-cdn.com/content/v1/620c07e40af1b05bc82bc766/1645127781291-7SID082LW9FP2WGVC6KB/Needels+020922+1.jpg Team (Copy) https://images.squarespace-cdn.com/content/v1/620c07e40af1b05bc82bc766/1654126257617-ZUJWA3VO1AYEHEJZ1TEL/SYNTHORX_Marcos%2BMilla%2B001.jpg Team (Copy)